Sociedad Americana de Hirudoterapia

Therapeutic Goods Administration

TGA · Australia · oceania

Regulatory jurisdiction profileJurisdictional reference
Medical device clearednational regulator

Australia's therapeutic-goods regulator — medicinal leeches included in the Australian Register of Therapeutic Goods (ARTG) as Class IIa medical device with import permit oversight.

Regulatory Profile

Agency type
national regulator
Region
oceania
Country
Australia
Leech status
medical device cleared
Last ASH review
2026-05-25

Relevant Regulation Codes

  • Therapeutic Goods Act 1989
  • Therapeutic Goods (Medical Devices) Regulations 2002
  • Biosecurity Act 2015 (live-invertebrate import)

Prescriber Requirements

  • Australian-registered medical practitioner prescription required; states/territories administer scope via AHPRA-registered professions
  • RN application under standing order; specialist nurse practitioners with wound-care endorsement within scope
  • Naturopaths are self-regulated post-2017 deregistration — leech therapy outside hospitals operates in unregulated grey zone

Supply Chain & GMP

ARTG entry mandatory; sponsor in Australia must hold equivalent of MDR Class IIa documentation. English-language IFU. Cold chain 4–10 °C.

Import/Export Rules

Biosecurity import permit from Department of Agriculture, Fisheries and Forestry (DAFF) required for live H. medicinalis. CITES Appendix II permit via Department of Climate Change, Energy, the Environment and Water (DCCEEW). Strict quarantine — Australia historically denied some leech imports on biosecurity grounds.

Reimbursement Context

Medicare Benefits Schedule (MBS) does not have a dedicated item for leech therapy; inpatient use covered via DRG (AR-DRG) bundling. Private health insurance variable.

ASH Editorial Notes

Australia's strict biosecurity regime (Quarantine Act 1908, now Biosecurity Act 2015) historically created supply constraints; current practice imports periodically rather than maintaining domestic breeding stocks.

Related Jurisdictions

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.